Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer

被引:23
|
作者
Marabese, Mirko [1 ]
Marchini, Sergio [1 ]
Marrazzo, Eleonora [1 ]
Mariani, Pietro [1 ]
Cattaneo, Dario [1 ]
Fossati, Roldano [2 ]
Compagnoni, Anna [2 ]
Signorelli, Mauro [3 ]
Moll, Ute M. [4 ]
Codegoni, A. Maria [1 ]
Broggini, Massimo [1 ]
机构
[1] Ist Farmacol Mario Negri, Dept Oncol, Mol Pharmacol Lab, Milan, Italy
[2] Ist Ric Farmacol Mario Negri, Dept Oncol, Lab Translat Res & Clin Outcome, Milan, Italy
[3] Univ Milano Monza, Osped san Gerardo, Milan, Italy
[4] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA
关键词
p53; p73; ovarian cancer; splice variants;
D O I
10.1016/j.ejca.2007.10.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The p53 gene has been investigated for its role in epithelial ovarian cancer but data collected until now are contradictory. The evidence that p53 belongs with p63 and p73 to a family of transcription factors re-opened interest in this gene family. Here, we used quantitative real time RT-PCR to determine expression levels of TAp53, TAp73 and their N-terminal splice variants in a cohort of 169 ovarian cancer patients with stage I and stage III disease. The TAp73 levels in stage III biopsies differed by 100-fold depending on the p53 status and overall survival appears to be significantly related to Delta Np73 expression. Kaplan-Meyer analyses did not suggest a correlation between overall survival and levels of TAp73, Delta Np73 or the Delta Np73/TAp73 ratio. In conclusion, these data suggest that at least in our patient cohort p53 and p73 expression levels are not correlated to malignant progression of ovarian cancer. They might, however, play a role in tumour initiation. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:131 / 141
页数:11
相关论文
共 50 条
  • [1] Expression levels of different p53 and p73 isoforms in ovarian cancer
    Marabese, Mirko
    Marchini, Sergio
    Marrazzo, Eleonora
    Mariani, Pietro
    Cattaneo, Dario
    Fossati, Roldano
    Compagnoni, Anna
    Signorelli, Mauro
    Moll, Ute M.
    Broggini, Massimo
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3499S - 3499S
  • [2] The effect of p53 isoforms on p73 activity in tumour cells
    Zoric, A.
    Horvat, A.
    Pavelic, J.
    Slade, N.
    EJC SUPPLEMENTS, 2010, 8 (05): : 165 - 165
  • [3] The impact of p53 and p73 on aneuploidy and cancer
    Tomasini, Richard
    Mak, Tak W.
    Melino, Gerry
    TRENDS IN CELL BIOLOGY, 2008, 18 (05) : 244 - 252
  • [4] p73, a grandpa of p53?
    Soussi, T
    M S-MEDECINE SCIENCES, 1997, 13 (12): : 1472 - 1473
  • [5] The p53/p63/p73 family of proteins - the focus on isoforms and mutants in cancer
    Slade, Neda
    Zoric, Arijana
    Horvat, Andela
    PERIODICUM BIOLOGORUM, 2010, 112 (04) : 425 - 432
  • [6] Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer
    Hofstetter, G.
    Berger, A.
    Fiegl, H.
    Slade, N.
    Zoric, A.
    Holzer, B.
    Schuster, E.
    Mobus, V. J.
    Reimer, D.
    Daxenbichler, G.
    Marth, C.
    Zeimet, A. G.
    Concin, N.
    Zeillinger, R.
    ONCOGENE, 2010, 29 (13) : 1997 - 2004
  • [7] Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer
    G Hofstetter
    A Berger
    H Fiegl
    N Slade
    A Zorić
    B Holzer
    E Schuster
    V J Mobus
    D Reimer
    G Daxenbichler
    C Marth
    A G Zeimet
    N Concin
    R Zeillinger
    Oncogene, 2010, 29 : 1997 - 2004
  • [8] When p53 needs p73 to be functional -: forced p73 expression induces nuclear accumulation of endogenous p53 protein
    Goldschneider, D
    Blanc, E
    Raguenez, G
    Haddada, H
    Bénard, J
    Douc-Rasy, S
    CANCER LETTERS, 2003, 197 (1-2) : 99 - 103
  • [9] p73 is transcriptionally regulated by DNA damage, p53, and p73
    Xinbin Chen
    Yiman Zheng
    Jianhui Zhu
    Jieyuan Jiang
    Jian Wang
    Oncogene, 2001, 20 : 769 - 774
  • [10] p73 is transcriptionally regulated by DNA damage, p53, and p73
    Chen, XB
    Zheng, YM
    Zhu, JH
    Jiang, JY
    Wang, J
    ONCOGENE, 2001, 20 (06) : 769 - 774